Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights

About this update from Q32 Bio Inc.

[{"type":"text","content":"- Reported Encouraging Initial Data from First Cohort of Phase 1 Trial Evaluating Gene Editing Candidate HMI-103 in Adults with PKU - - Evaluating Strategic Options for the Company and Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates. “We recently shared the encouraging initial data from the first dose level of the pheEDIT trial evaluating gene editing candidate HMI-103 for PKU, which showed a one-time administration was generally well-tolerated in all three participants, and two participants achieved meaningful reductions in plasma Phe as of the cut-off date of July 26, 2023,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “Despite these data, we are evaluating strategic options for the Company and our genetic medicines pipeline due to the current financing environment and the expected clinical development timeline for HMI-103.” Second Quarter 2023 and Recent Accomplishments Announced encouraging initial clinical data from the first dose cohort of the pheEDIT clinical trial evaluating HMI-103 gene editing candidate for phenylketonuria (PKU), and today announced approval from the independent Data Monitoring Committee to escalate to the next dose cohort in the trial. As of the data cut-off date of July 26, 2023, HMI-103 was generally well-tolerated in all three participants.Participant 1 experienced a clinically meaningful reduction in plasma phenylalanine (Phe) levels to below the U.S. American College of Medical Genetics and Genomics (ACMG) PKU treatment guideline threshold of","length":2436,"tagName":"div"}]

More updates from Q32 Bio Inc.